PMID: 518175Dec 1, 1979Paper

The use of arm veins in femoral-popliteal bypass grafts

Annals of Surgery
D R CampbellG W Gibbons

Abstract

In view of the increasing debate as to the best alternative to saphenous vein for femoral popliteal bypass grafts, we present our experience with the use of arm vein grafts. Though there are many anecdotal reports, only one series has been previously published. Arm veins were used when saphenous vein was unavailable in 18 femoral popliteal or femoral tibial bypass grafts. Eighty-three per cent of the patients were diabetic. Ninety-four per cent of the patients were operated on for limb salvage, and in 67% the arteriograms showed only fair to poor run-off. Despite this, the one year patency rate was 82%, which is significantly better than the sixty-nine per cent one year patency rate reported by the senior author in an earlier series using cloth grafts. In view of these good results, we believe that autogenous vein remains the material of choice in femoral popliteal bypass grafts. We do not feel that expanded polytetrafluoroethylene grafts or umbilical vein grafts have yet been shown to be superior. We emphasize also the special techniques that are required when using arm veins.

References

Nov 1, 1976·Archives of Surgery·K R ClaysonA Dale

❮ Previous
Next ❯

Citations

Dec 1, 1996·Journal of Vascular Nursing : Official Publication of the Society for Peripheral Vascular Nursing·M B LovellW G Jamieson
Jul 27, 2001·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·F C Brochado-NetoM Cinelli
Apr 1, 1995·Journal of Vascular Surgery·T J HölzenbeinF W LoGerfo
Jan 1, 1989·The British Journal of Surgery·J A Michaels

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.